Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Reduced Aß Amyloid Deposits Relate to Inflammation and Neuronal Survival in Multiple Sclerosis Cortex
Multiple Sclerosis
S17 - Multiple Sclerosis: Immunology/Basic Sciences (1:24 PM-1:36 PM)
003

Multiple sclerosis (MS) and Alzheimer’s disease (AD) represent major foci of interest for neuropathological research. MS is the quintessential neuroinflammatory disease, but inflammation is increasingly recognised as an independent driver of AD pathology, with microglial activation thought to play a key role. One might expect amyloid deposition in the MS brain given that the pathological hallmarks of amyloid plaques and neurofibrillary tangles seen in AD are also seen to a lesser extent in the normal aging brain. Moreover, coexistence of MS and AD pathology is likely since there is anatomical overlap in the cortical areas affected. The chronic inflammatory milieu of the MS cortex thus provides a unique model in which to further investigate the role that inflammation plays in amyloid physiology.

We investigated the Aβ burden in post-mortem samples of temporal or frontal cortex in MS and evaluate its relationships with motor cortical pathology.

An autopsy cohort of pathologically confirmed MS (n=78) and control (n=67) cases was used, where Aβ burden was related to neuronal and microglial/macrophages densities. Quantitative and semi-quantitative analyses were performed and related to pathological features.

We found reduced Aβ burden in normal-appearing grey matter of MS cases that died below median age (64 years-old) compared with matched controls, with further reduction noted in MS-specific subpial demyelinated lesions. An increase in CD68+ microglial/macrophage expression and neuronal survival related to the reduction in Aβ was found in MS cases that died below median age.

These findings suggest that MS-related factors, including microglia/macrophage inflammation, influence Aβ deposition and neurodegeneration thereby highlighting new therapeutic perspectives relevant for both MS and AD.

Authors/Disclosures
Jonathan Pansieri, PhD (University of Oxford)
PRESENTER
The institution of Dr. Pansieri has received research support from UK-MS society. The institution of Dr. Pansieri has received research support from Department of Defense US. Dr. Pansieri has received personal compensation in the range of $0-$499 for serving as a member of the Grant review Panel with French National Agency. Dr. Pansieri has received personal compensation in the range of $500-$4,999 for serving as a recipee of Travel Grant with Brain.
Marco Pisa, MD (Nuffield Department of Clinical Neurosciences, University of Oxford) Dr. Pisa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.
Alissa Gutnikova No disclosure on file
Elliott Ridgeon No disclosure on file
Richard Hickman No disclosure on file
Margaret Esiri No disclosure on file
Gabriele C. De Luca, MD, DPhil, FAAN (University of Oxford) Dr. De Luca has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurology Academy. Dr. De Luca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. De Luca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. De Luca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. The institution of Dr. De Luca has received research support from NIHR, BRC (Oxford). The institution of Dr. De Luca has received research support from National Health and Medical Research (Australia). The institution of Dr. De Luca has received research support from UK MS Society. The institution of Dr. De Luca has received research support from Oxford-Quinnipiac Partnership. The institution of Dr. De Luca has received research support from US Department of Defense. The institution of Dr. De Luca has received research support from Wellcome ISSF (Oxford). The institution of Dr. De Luca has received research support from Bristol Myers Squibb. The institution of Dr. De Luca has received research support from University of Oxford (John Fell Fund). Dr. De Luca has a non-compensated relationship as a Editorial board member with MS Journal that is relevant to AAN interests or activities. Dr. De Luca has a non-compensated relationship as a Vice-Chair of Grant Review Panel with UK MS Society that is relevant to AAN interests or activities. Dr. De Luca has a non-compensated relationship as a Steering Group member with MS Academy that is relevant to AAN interests or activities.